Dialogue Health Technologies (OTCMKTS:DLHTF – Get Rating) had its price objective lowered by Canaccord Genuity Group from C$8.00 to C$6.00 in a research report released on Wednesday, The Fly reports. The brokerage currently has a buy rating on the stock.
Several other equities analysts have also recently issued reports on DLHTF. Royal Bank of Canada dropped their price target on shares of Dialogue Health Technologies from C$7.00 to C$6.00 in a research note on Monday, August 15th. Scotiabank dropped their price target on shares of Dialogue Health Technologies from C$8.50 to C$8.00 in a research note on Friday, August 12th. TD Securities dropped their price target on shares of Dialogue Health Technologies from C$4.50 to C$3.50 in a research note on Wednesday. Finally, National Bank Financial dropped their price target on shares of Dialogue Health Technologies from C$11.50 to C$8.50 in a research note on Tuesday, August 9th.
Dialogue Health Technologies Trading Down 11.5%
Shares of OTCMKTS:DLHTF opened at 2.07 on Wednesday. Dialogue Health Technologies has a one year low of 2.07 and a one year high of 4.75.
About Dialogue Health Technologies
Dialogue Health Technologies Inc operates a digital healthcare and wellness platform in Canada Germany, and Australia. Its Integrated Health Platform is a healthcare hub that centralizes its programs in a single user-friendly application, which provides access to psychologists, psychotherapists, social workers, physicians, nurses, and health specialists.
Receive News & Ratings for Dialogue Health Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dialogue Health Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.